Evidence map›Paper›PMID 31168396›Full record

ArticleLupus science & medicine2019

L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells.

Joy N Jones Buie, Dorea Pleasant Jenkins, Robin Muise-Helmericks, Jim C Oates

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. The endothelium response to kidney injury.Nature reviews. Nephrology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Endothelial cells: potential novel regulators of renal inflammation.American journal of physiology. Renal physiology · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Joy N Jones BuieDepartment of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.
Dorea Pleasant JenkinsDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, South Carolina, USA.
Robin Muise-HelmericksDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, South Carolina, USA.
Jim C OatesDepartment of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA.
Medical University of South Carolina · US

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
T-COHR: Training in Craniofacial and Oral Health ResearchT32DE017551 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YAO, HAI · 2006 to 2025
$10.3M
Resource CoreP30AR072582 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JAMES C OATES · 2017 to 2026
$8.5M
Patient Resource CoreP60AR062755 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SILVER, RICHARD M. · 2012 to 2016
$5.8M
Role of reactive intermediates in lupus nephritisR01AR045476 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GILKESON, GARY S, OATES, JAMES C · 1999 to 2012
$3.5M
Training in Bioenergetics, Oxidative Stress and Metabolic SyndromeT32DK083262 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LEMASTERS, JOHN J · 2009 to 2018
$1.5M
Targeting Pathogenic Endothelial Dysfunction in Systemic Lupus ErythematosusI01CX001248 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI OATES, JAMES C · 2016 to 2025
–
CSRD VA I01 CX001248NCATS NIH HHS UL1 TR001450NIAMS NIH HHS P30 AR072582NIAMS NIH HHS P60 AR062755NIAMS NIH HHS R01 AR045476NIDCR NIH HHS T32 DE017551NIDDK NIH HHS T32 DK083262
6 · The paper itself

Abstract

objectiveSLE serves as an independent risk factor` for endothelial dysfunction (ED) not explained by Framingham risk factors. We sought to understand the development of SLE-induced ED on a cellular level in order to develop strategies aimed at reversing cellular abnormalities. This study assessed the impact of SLE patient serum on endothelial nitric oxide synthase (eNOS), nitric oxide (NO) production and functional changes in the cell.

methodsHuman umbilical vein endothelial cells (HUVECs) cultured in serum of either SLE (n=25) or healthy patients (n=14) or endothelial basal medium 2 (EBM-2) culture media supplemented with fetal bovine serum with or without L-sepiapterin were used for our studies. We applied the fluorescent probe DAF-FM diacetate for intracellular NO detection using flow cytometry. Total RNA isolates were analysed using reverse transcription PCR for eNOS mRNA expression. Oxygen consumption rate was determined using seahorse analysis. Neutrophil adhesion and migration were determined using a calcein AM microscopy assay.

resultsThe mRNA expression of eNOS was increased in SLE cultured HUVECs compared with healthy control (p<0.05). The SLE eNOS mRNA level correlated with SLE patient age (p=0.008); however, this trend was not observed with healthy patients. SLE serum reduced NO production in HUVECs compared with EBM-2 cultured cells (p<0.05). Co-treatment of endothelial cells with L-sepiapterin preserved HUVEC capacity to produce NO in SLE conditions (p<0.01). SLE serum enhanced neutrophil migration (p<0.01) but not neutrophil adhesion compared with healthy controls. The bioenergetic health index was not different.

conclusionsSLE likely causes disruption of endothelial cell eNOS function and NO modulated pathways.

Indexed as

endothelial dysfunctionendothelial nitric oxide synthaseL-sepiapterinnitric oxidesystemic lupus erythematosus

Identifiers

PMID31168396
PMCPMC6519412
OpenAlexW2916740976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.